厄贝沙坦延缓高血压合并糖尿病肾病患者肾病的进展
发布时间：2018-07-15 09:36
【摘要】：目的本研究旨在评估厄贝沙坦在治疗高血压(HBP)合并糖尿病肾病(DN)患者中对肾病进展的延缓作用。方法本研究为单中心、随机、平行对照临床试验,共纳入180例HBP合并DN患者。患者按照区组随机方式1∶1分配至厄贝沙坦组和氨氯地平组。结果治疗12个月后,厄贝沙坦组估算肾小球滤过率(e GFR)下降值低于氨氯地平组(P=0.026)。CKDⅠ~Ⅱ期患者中,厄贝沙坦组e GFR下降值低于氨氯地平组(P=0.038),在CKDⅢ期患者中结果类似(P=0.042)。12个月时厄贝沙坦组24 h蛋白尿降低水平显著高于氨氯地平组(P0.001),2组间DBP(P=0.534)和SBP(P=0.386)下降值无统计学差异。结论厄贝沙坦治疗HBP合并DN患者,可以一定程度延缓患者的肾病进展。
[Abstract]:Objective to evaluate the effect of irbesartan on the progression of hypertension (HBP) with diabetic nephropathy (DN). Methods 180 HBP patients with DN were enrolled in a single center, randomized, parallel controlled clinical trial. Patients were randomly assigned to irbesartan and amlodipine groups at 1:1. Results after 12 months of treatment, the decrease of estimated glomerular filtration rate (eGFR) in irbesartan group was lower than that in amlodipine group (P0. 026). The decrease of eGFR in irbesartan group was lower than that in amlodipine group (P0.038), and the results were similar in CKD 鈪，
本文编号：2123632
[Abstract]:Objective to evaluate the effect of irbesartan on the progression of hypertension (HBP) with diabetic nephropathy (DN). Methods 180 HBP patients with DN were enrolled in a single center, randomized, parallel controlled clinical trial. Patients were randomly assigned to irbesartan and amlodipine groups at 1:1. Results after 12 months of treatment, the decrease of estimated glomerular filtration rate (eGFR) in irbesartan group was lower than that in amlodipine group (P0. 026). The decrease of eGFR in irbesartan group was lower than that in amlodipine group (P0.038), and the results were similar in CKD 鈪，
本文编号：2123632
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2123632.html
最近更新
教材专著
